Tivozanib

CAS: 475108-18-0

Ref. TR-T447205

Produktinformation

• Name: Tivozanib
• Synonyme: Urea, N-[2-chloro-4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(5-methyl-3-isoxazolyl)-, N-[2-Chloro-4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(5-methyl-3-isoxazolyl)urea, AV 951, KRN 951, Kil 8951, N-[2-Chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl]-N'-(5-methyl-3-isoxazolyl)urea, 1-[2-Chloro-4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-3-(5-methyl-1,2-oxazol-3-yl)urea, Av-951, Fotivda, Krn 951, N-[2-Chloro-4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N′-(5-methyl-3-isoxazolyl)urea, Urea, N-[2-chloro-4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N′-(5-methyl-3-isoxazolyl)-

Beschreibung

Applications Tivozanib is known as an oral VEGF receptor tyrosine kinase inhibitor, exhibiting antitumor effects towards renal cell carcinoma.. Tivozanib suppresses angiogenesis by selectively inhibiting against vascular endothelial growth factor. Potent VEGFR inhibitor.
References Nosov, D.A., et al.: J. Clinical. Oncol., 30, 1678 (2012); Pal, S.K., et al., Molec. Cancer. Thr, 11, 526 (2012);

• Marke: TRC

Chemische Eigenschaften

• Molekulargewicht: 454.86
• Formel: C₂₂H₁₉ClN₄O₅
• Farbe/Form: Neat
• InChl: InChI=1S/C22H19ClN4O5/c1-12-8-21(27-32-12)26-22(28)25-16-5-4-13(9-15(16)23)31-18-6-7-24-17-11-20(30-3)19(29-2)10-14(17)18/h4-11H,1-3H3,(H2,25,26,27,28)
• InChI Key: InChIKey=SPMVMDHWKHCIDT-UHFFFAOYSA-N
• SMILES: COc1cc2nccc(Oc3ccc(NC(=O)N=c4cc(C)o[nH]4)c(Cl)c3)c2cc1OC